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Chronicnoncancerpainisaprevalentproblemassociatedwithpoorqualityoflife.Whilesymptomburdenisfrequentlymentioned
in the literature and clinical settings, this research highlights the considerable negative impact of chronic pain on the individual.
The 15D, a measure of health-related quality of life (HRQOL), is a user-friendly tool with good psychometric properties. Using
a modiﬁed edmonton symptom assessment scale (ESAS), we examined whether demographics, medical history, and symptom
burden reports from the ESAS would be related statistically to HRQOL measured with the 15D. Symptom burden, medication
detriment scores, and number of medical comorbidities were signiﬁcant negative predictors of 15D scores with ESAS symptom
burden being the strongest predictor. Our ﬁndings highlight the tremendous symptom burden experienced in our sample. Our
data suggestthatheavier prescription medicationtreatment forchronic pain hasthepotential to negatively impact HRQOL.Much
remains unknown regarding how to assess and improve HRQOL in this relatively heterogeneous clinical population.
1.Introduction
“Chronic noncancer pain” (CNCP) is a shorthand medical
description for a constellation of symptoms in which indi-
viduals report pain for prolonged periods of time in the
speciﬁc absence of incurable cancer. This distinction is
made because the goals of and limitations upon symptom
control in cancer versus noncancer pain are diﬀerent.
This pain may either be associated with a demonstrable,
incurable structural illness or injury which is known to
cause pain (such as arthritis or nerve damage), may continue
long after the apparent structural resolution of such an
illness or injury, or exist without any apparent structural
explanation at all. Chronic noncancer pain conditions are
very common in the industrialized world and are increasing
in prevalence [1]. In some cases, it is associated with severe
disability. Its direct and indirect costs to the suﬀerer and
society as a whole are signiﬁcant and well documented
[2].
Whileobjectivephysicalcorrelatesofpainexist, theexpe-
rienceofpainisentirely subjective[3].The person’sreport of
its presence and intensity is, therefore, deﬁnitive. Moreover,
pain intensity ﬂuctuates on a continuous basis and is also
known to be aﬀected by circumstance, thoughts, and feelings
[4, 5]. The burden of symptoms experienced by chronic
pain suﬀerers is frequently shared in clinical settings. These
and other factors make pain intensity reduction a diﬃcult
outcomefortherapiststouseasameasureoftheeﬀectiveness
of their care. Many clinicians place a high emphasis on
observable improvements in health-related quality of life
(HRQOL) as exemplars of successful treatment [6, 7].
Summary measures of HRQOL, whether obtained from
structured interviews or, more commonly, questionnaires,
are attractive to clinicians and researchers. They permit stan-
dardization of the data gathering process and render quanti-
tativeHRQOLmeasuresthatcanbeusedtomonitorindivid-
uals’ progress with standard treatment, evaluate experimen-
tal treatment, or to compare HRQOL in populations with2 Pain Research and Treatment
diﬀerent characteristics. A plethora of HRQOL-measuring
techniques are available [8], but there is no consensus on
which tool has the best combination of reliability, validity,
eﬃcacy, and ease of use for the chronic pain population.
As a part of our Multidisciplinary Pain Centre’s mandate
toprovide clinicalcare while extending the boundaries ofthe
clinical research literature, we chose to explore HRQOL in
our clinic population and compare it to data collected from
another symptom scale previously adapted for use in our
centre. In this paper, we describe the comparison of HRQOL
measured by the 15D to the Edmonton symptom assessment
scale [ESAS; 12]. The purpose of the present research was
to determine whether there was a statistical relationship
between HRQOL scores rendered by 15D and chronic
noncancer pain—speciﬁc symptom burden measured by
ESAS, with the speciﬁc null hypothesis that there would be
no such relationship.
2.Materialsand Methods
The Multidisciplinary Pain Centre at the University of Alber-
ta Hospital in Edmonton, Alberta, is an out-patient referral
facility for persons with chronic pain. The centre’s patient
population tends to deal with more complex and intractable
pain problems than is often seen in most medical settings,
accompanied by high degrees of medical comorbidity and
mood disorders (e.g., depression and anxiety disorders).
T h e r ei sn oc h a r g et ot h ep a t i e n tf o ra t t e n d i n gi fh eo r
she possesses valid health insurance from one of Canada’s
provincial health programs.
The 15D [9, 10] is a preference-based, generic, self-
administered measure ofHRQOL.Itencompasses 15dimen-
sions: mobility, vision, hearing, breathing, sleeping, eating,
speech, elimination, the ability to perform usual activities,
thinking and memory, discomfort and symptoms, depres-
sion, distress, vitality, and sexual activity. These factors are
commonly measured in HRQOL instruments to capture
a broad range of facets of life aﬀected by health and
particularly, poor health. Each dimension of the 15D is
divided into 5 levels, from which the respondent selects the
one which best describes his or her current state. Algorithms
then employ a set of population-based preference or utility
weights used to convert these scores into a utility, ranging
from 0.00–1.00, respectively, indicating the value of death
versus perfect health (no problems in any dimension). The
15D is easy to administer and respond to and has been
demonstratedtohavegoodtest-retestreliabilityanddiscrim-
inatory power that is comparable to other preference based
instruments [10]. It is also available in the public domain
withoutthesomewhatprohibitivecostsassociated withother
instruments. The 15Dhasbeenusedasameasure ofHRQOL
in chronic pain populations before [11]. However, although
intuitively suitable for this purpose, we have been unable to
ﬁnd any publications comparing the use of the 15D to other
measures of HRQOL in this patient population.
While a number of HRQOL measures have been used
in CNCP studies, there is no gold-standard measure against
which to compare 15D when seeking to quantify HRQOL
in the chronic pain population. As a result, the opportunity
to compare its discriminatory function to other pain-speciﬁc
instruments has thepotentialtoaddmeaningful information
to the published literature.
The ESAS [12] is a nine-item questionnaire, originally
developed for the quantitative longitudinal assessment of
distressing symptoms in patients receiving palliative care.
The intensity of each of nine standard symptoms is reported
on a 0–10 visual analogue scale, and there is the option for
the respondent to add an additional tenth named symptom.
These individual scores are then summed to give a total
score. Our centre has adapted the ESAS for use in our CNCP
population due to its ability to track symptom ﬂuctuation
in our chronic disease management setting. We adapted the
ESAS originally to monitor symptom burden and patient
progress in our centre years before we adopted the 15D as
a standard outcome measure of HRQOL in our centre.
Aspartoftheirinitialintakeassessment, allpatientscom-
pleted the 15D. ESAS was also completed at intake and at
each followup appointment. Patients completed the instru-
ments with assistance from the clinic nurse.
We retrospectively examined the records of 100 consecu-
tive ﬁrst attendees from February to October 2006. For each
subject, we recorded age, gender, duration of pain, number
of pain sites, and comorbid illnesses. We recorded the names
and doses of each medication being used chronically, then
quantiﬁed the total burden of each subject’s medication
usingthemedicationquantiﬁcationscoreIII(MQS-III)[13],
which assigns a measurement to each drug based on both
the dose taken and its burdensomeness (derived from expert
consensus). The 15D was recorded as described. ESAS at the
intake visit was recorded using the following symptom cat-
egories: pain, tiredness, nausea, depression, anxiety, energy
level, well-being, drowsiness, and constipation. Changes to
the original published ESAS inventory were made in order
to eliminate symptoms with limited relevance outside the
palliative care context (lack of appetite and shortness of
breath), to reword one symptom to make it more relevant for
chronic pain patients (“activity”), and to include two others
that are frequently cited by our population (tiredness and
constipation). The optional tenth symptom was not added.
Scores for “well-being” and “energy” were inverted prior to
summing individual symptom scores to yield a total score
with a potential range from 0–90.
Statistical analysis was performed using SAS version 9.2
for Windows. Descriptive statistics were obtained for the
demographicvariables and thetwoHRQOLmeasures. Using
simple linear regression (PROC REG) with a backwards
variable elimination algorithm, exploratory analysis of the
relative eﬀect of each of the other variables (age, gender,
pain duration, number of pain sites, medication score, and
number ofcomorbiditiesandESAS)on15D summary scores
was performed in order to determine which variable(s)
demonstrated the strongest independent correlation. The
signiﬁcance level for a variable to remain in the model at
each stage was set at 0.05. To better illustrate the strength
of signiﬁcant associations, we then derived Pearson’s rank
correlation coeﬃcient for the relationship between each of
them and 15D.Pain Research and Treatment 3
Table 1: Summary of participant characteristics.
Variable Mean Std Dev Median IQR Minimum Maximum
Age (yr) 48.7 15.8 49 19 17 92
Pain Duration (yr) 9.4 10.0 6 7 0.5 50
Number of Pain Sites 2.1 1.7 1 2 1 12
Number of comorbidities 1.0 1.3 1 2 0 6
MQS 13.3 11.0 12 12 0 42
ESAS 38 8 39 5 16 62
15D score 0.67 0.15 0.66 0.22 0.32 0.95
Table 2: Pain sites reported.
Site % of sites reported (n = 213)
Back, hips, and buttocks 24
Lower extremity 23
Widespread 17
Chest 10
Head, face or jaw 8
Upper extremity 8
Neck 6
Abdomen, pelvis, and genitalia 6
Shoulder 5
Phantom 0.5
The Health Research Ethics Board of the University of
Alberta approved this research with the consent of each
participant.
3.Results
The subject group is described in Tables 1, 2,a n d3.T h e
sample comprised 65% females. The typical subject was a
person in middle age with a six-year pain history, one other
medical or psychiatric comorbidity, and an MQS-III of 12,
but pain duration, the number of pain sites, comorbidity
count and MQS-III were all right skewed by a minority of
subjects with much greater burdens in these areas. Fifty-
eight percent of the subject group was consuming opioid
analgesics. These ranged from short-acting low-potency
opioids to high-dose long-acting preparations. Daily oral
morphine equivalent doses ranged from 15 to 4800mg/day
(mean 292mg, median 100mg, IQR 143mg). Other pain-
related medications were also in common use, such as
antidepressants (25%), NSAIDs (20%), sedative/hypnotics
15%, and anticonvulsants (11%). Table 4 contains summary
measures of MQS-III, ESAS and 15D. Graphical summaries
of the responses to the component items of the 15D and
ESAS are given in Figure 1. Correlations for the 15D, ESAS,
and the number of comorbidities can be found in Table 5.
Of the dependent variables entered into the exploratory
regression analysis, only ESAS,MQS, and number of comor-
bidities were retained as independent negative predictors of
15D (Table 4). ESAS showed the strongest association. The
R2 for the model, (indicating the proportion of the total
variancein15Dthatwasexplicablebythepredictorsentered)
was 0.31.
From a somewhat more qualitative standpoint, visual
inspection of the histograms in Figures 1 and 2 highlights
trends that are consistent with what is reported by indi-
viduals with chronic pain in Centers such as ours. The
15D/ESAS ratings of discomfort/pain, sleeping/tiredness,
usual activities and well-being are all skewed toward patterns
of experiencing increased problems and/or disability in
these domains. There is clear convergence in these domains
between questionnaires. As well, each of these areas is key to
a person’s global experience of quality of life. A somewhat
unexpected trend was also noted that suggested a lower
level of depression in this sample than is often reported
in a center such as ours that deals with complex chronic
pain [14]. It may be that antidepressant treatment in this
population instituted prior to attending our clinic reduced
the depression scores on the 15D.
4.Discussion
We have demonstrated inverse associations between
HRQOL, as measured by the 15D instrument, and symptom
burden in patients attending a referral treatment facility for
chronic noncancer pain. This association is plausible and
clinically relevant. Our null hypothesis is rejected.
In attempting to determine the degree of colinearity
between 15D and ESAS, our ﬁrst requirement was that the
study sample contains suﬃcient number of individuals who
represented all degrees of symptom burden. In this respect,
we are satisﬁed with the wide variation we recorded in both
of these measures. The overall degree of symptom burden in
our sample was high: The median ESAS score was 39 out
of a possible 90. In contrast, a sample of medical oncology
inpatients recorded median scores of 24.9 [15], while a series
of patients receiving renal dialysis recorded mean scores
equivalent to 34.1 [16]. Summary 15D scores are utilities,
which is to say that a score 0.00 as represents a health state
that is equivalent, in the respondent’s mind to death, and
1.00 to perfect health. Using diﬀerent methodology, Gold
et al. [17] derived utilities for a large number of diﬀerent
medical states using data drawn from and validated on a
large population sample of Americans, which enables us to
contextualize our results. Our sample had a median utility of
0.66. In Gold’s study of 131 named common conditions or
disease states aﬀecting all body systems, the lowest median4 Pain Research and Treatment
Table 3: Comorbidities by system (excluding 44 subjects reporting none).
Diagnostic category Diagnosis No. of patients
Psychiatric
Depression 9
Anxiety 2
All psychiatric 11
CNS
Stroke 3
Migraine 1
Restless leg syndrome 1
Vertigo 1
Glaucoma 1
All CNS 7
Cardiovascular
Hypertension 11
Coronary disease 2
Valvular disease 2
All cardiovascular 15
Respiratory
COPD 2
Asthma 1
Sleep Apnea 1
All respiratory 4
Gastrointestinal
Reﬂux/dyspepsia 4
Inﬂammtory bowel disease 3
Irritable bowel syndrome 2
Fatty liver 1
Gallstones 1
Not speciﬁed 1
All gastrointestinal 12
Endocrine
Obesity 7
Hypercholesterolemia 4
Hypothyroidism 3
Diabetes 1
Osteoporosis 1
All endocrine 16
Renal
Chronic renal failure 2
Kidney transplant 1
All renal 3
Infectious
Hepatitis C 4
HIV 1
All infectious 5
Connective tissue/joint
disorders
Osteoarthritis 3
Dematomyositis 1
Lupus 1
Vascultis 1
Congenital hip dislocation 1
All connective tissue/joint 7
Miscellaneous
Cancer in remission 3
Former street drug user 1
Data missing 1
All miscellaneous 5Pain Research and Treatment 5
Table 4: Independent predictors of 15D index from regression model.
Variable Parameter estimate Standard error F Pr > |F|
Intercept 0.9151 0.0745 150.77 <.0001
ESAS −0.0074 0.0016 20.62 <.0001
MQS −0.0033 0.0012 8.23 0.0051
Number of Comorbidities −0.0230 0.0098 5.48 0.0213
R2 = 0.31.
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Figure 1: Number of responses to the component items of the ESAS.
Table 5: Signiﬁcantcorrelations with 15D index.
ESAS MQS No. of comorbidities
r∗ −0.42 −0.31 −0.22
P <.0001 0.002 0.026
∗Pearson’s coeﬃcient.
utility was 0.21 (for hemiplegia) and the highest was 0.92
(for a number of conditions including acne, color blindness
and hay fever). Nonpain conditions with median utilities
equivalent to that reported by our chronic pain sample
include retinal disease, absence of one hand or arm, breast
cancer, and tachycardia.
One signiﬁcant independent correlate of reduced
HRQOL was the number of comorbidities reported by the
subject. This is in keeping with recent work in which we
derived independent risk factors for chronic pain in a large
Canadian population sample [18]. This indicated that many
chronic medical conditions are positively associated with
chronic pain, even those, such as thyroid disease and COPD
that are not conventionally thought of as being painful.
The high median MQS-III, indicating extensive use of
prescription medication, is not surprising given the level of
prescription medication use in Canada in general and for6 Pain Research and Treatment
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Figure 2: Number of responses to the component items of the 15D.
pain in particular [19].Evenso, this amount of consumption
corresponds to the daily intake of the most potent opioid
analgesic in the upper 50% of the therapeutic dose range
[13]. Clinicians generally believe that by seeking to lower
painintensitywithstronganalgesics,theattenuationofsocial
functioning associated with chronic pain will be reversed,
primarily because pain is invoked as the reason for this
decrease in functioning. Our results would seem to suggest
that more intense drug treatment is not, in fact, associated
with improved HRQOL. This may merely be a reﬂection
of the fact that our sample was composed of ﬁrst-time
attendees to a referral centre, and thus it is biased towards
those in whom drug treatment had not provided adequate
pain control. An alternative interpretation, however, is that
despite the salience of the link between pain intensity and
decreased functioning, these are both simply consequences
of a third, undescribed factor. Alternatively still, potent
medicationsmaybefelttobeusefulbypatientsandclinicians
even though they worsen some aspects of HRQOL (because
of side eﬀects) or do not change it.
ESAS, MQS and the number of comorbidities between
them only explained 31% of the variance in 15D that
our sample reported. We know that HRQOL is a complex
constructthat reﬂectsmore thansymptom burden.InGold’s
study, for example, persons with ‘paraplegia’ and those with
“paralysis of the entire body” gave similar HRQOL scores,
notwithstanding the fact that one would expect those with
the continuing use of their arms to be less burdened. There
are clearly subjective determinants of HRQOL that are not
captured by the instruments we used. Most likely, there may
also be important symptoms that are burdensome to chronic
pain patients, but that were not captured in ESAS.
It may be worth noting that the distribution of ESAS
scores visually appears to peak on some speciﬁc scores more
than one might expect. There seems to be a disproportionate
number of scores of 3 and 7 in our sample. While we have no
data-drivenhypotheses forthispattern,it ispossible thatthis
ﬁnding represents some kind of a response bias that requires
further study when evaluating the use of the ESAS in this
population.
5.Conclusion
Our ﬁndings suggest that the 15D is appropriate for use for
individuals with chronic pain. As well, to the best of our
knowledge,thisistheﬁrst publishedstudythat haspresented
the use of the ESAS in a chronic pain population. While
our methods do not formally validate its use statistically,
our ﬁndings suggest that our modiﬁed ESAS has strong
ecological validity and at least some degree of convergent
validity when comparing some ESAS items to corresponding
15Ditems.FurtherstudyofhowtheESAScouldbebeneﬁcial
for use with chronic pain populations is needed.Pain Research and Treatment 7
Ourstudyincludesacross-sectionalanalysisofacomplex
hierarchy of determinants of health which are necessarily
highly subjective in nature and rapidly changing. We have
simply compared two diﬀerent instruments, and we did not
use a gold standard, since none exists. Nonetheless, our
results suggest that the 15D instrument may be of use in the
chronic pain clinic population to quantify general HRQOL
as a utility measurement. This would permit cross-sectional
comparisons between chronic pain and other conditions,
the evaluation of therapeutic interventions over time, and
the conduct of cost-eﬀectiveness and cost-utility analy-
ses in this clinically, socially, and economically important
condition.
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